About Genomtec
Genomtec is a company based in Wrocław (Poland) founded in 2016. Genomtec has raised $4.38 million across 6 funding rounds from investors including European Union, PARP and National Research Development Corporation. Genomtec offers products and services including Genomtec ID, Genomtec Tumor, Genomtec SARS-CoV-2 EvaGreen, and Genomtec RT-LAMP Duo Kit. Genomtec operates in a competitive market with competitors including Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
- Headquarter Wrocław, Poland
- SectorsHealthcare
- Email••••••••
- Website genomtec.com
- Social LinkedIn YouTube
- Legal Name Genomtec Sa
- Annual Revenue$5.85 K (USD)2000as on Dec 31, 2025
- Net Profit-$2.9 M (USD)6.93as on Dec 31, 2025
- EBITDA-$3.33 M (USD)-7.71as on Dec 31, 2025
- Total Equity Funding$4.38M (USD)
in 6 rounds
- Latest Funding Round$5.49M (USD), Grant
Dec 2023
- InvestorsEuropean Union
& 4 more
Products & Services of Genomtec
Genomtec offers a comprehensive portfolio of products and services, including Genomtec ID, Genomtec Tumor, Genomtec SARS-CoV-2 EvaGreen, and Genomtec RT-LAMP Duo Kit.
Mobile platform for point-of-care genetic diagnostics.
Platform for genetic analysis in oncology applications.
Kit for detecting SARS-CoV-2 through genetic methods.
Kit for rapid genetic testing in various applications.
Apps and channels of Genomtec
its YouTube channel Genomtec. Genetic mobile lab right away at POC. has 134 subscribers and 30 videos.
Videos from Genomtec
The most watched videos on Genomtec's YouTube channel, Genomtec. Genetic mobile lab right away at POC. (134 subscribers). Click a video to play it here.
Funding Insights of Genomtec
Genomtec has successfully raised a total of $4.38M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $5.49 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.38M
- Total Rounds 6
- Last Round Grant — $5.49M
- First Round $2.29M
(Jan 2019)
- Investors Count 5
All 6 funding rounds of Genomtec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $5.49M | Grant | – | – | |
| Apr 2023 | $3.2M | Series A | – | – | – |
| Oct 2020 | $1.18M | Seed | – | KnowledgeHub | – |
| Apr 2020 | $54,286 | Grant | – | – | |
| Nov 2019 | $55,952 | Grant | – | – | |
| Jan 2019 | $2.29M | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Genomtec
Genomtec has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, PARP and National Research Development Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | kh.vc | - | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Management consulting and business management services are provided. | 2000 | parp.gov.pl | Warsaw, Poland | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Technology commercialisation services are provided to clients. | 1953 | nrdcindia.com | Delhi, India |
Investor details for Genomtec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genomtec
3 people are tracked at Genomtec (3 in leadership).
| Name | Role | Group |
|---|---|---|
Damian Andrzejewski | ex-CEO | Leadership |
Miron Tokarski | Chief Executive Officer | Leadership |
Michał Wachowski | Chief Financial Officer | Leadership |
Complete people profiles for Genomtec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genomtec
Genomtec is a publicly listed company on the GPW with ticker symbol GMT in Poland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Mar 2021
- Listed onGPW: GMT
- Listed entityGenomtec SA
- Exchange sectorHealth technology
- ISINPLGNMTC00017
- Share price3.05 PLN (-0.65% on the day) · 2026-10-12
- Market capitalisation52,388,426.00 PLN
- EPS (diluted, trailing year)-0.52 PLN
- Volume (last session)30,732
Financials of Genomtec
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 21,000 PLN | -10.4M PLN | -12.0M PLN |
| 2024 | 1,000 PLN | -11.2M PLN | -11.1M PLN |
| 2023 | 1,000 PLN | -9.0M PLN | -8.9M PLN |
| 2022 | 40,000 PLN | -11.9M PLN | -11.1M PLN |
| 2021 | 219,000 PLN | -7.1M PLN | -10.0M PLN |
Detailed financial statements for Genomtec
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Genomtec
4 dated milestones of Genomtec across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Genomtec is founded.
- Funding First funding round of $2.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $5.5M.
Competitors of Genomtec
Genomtec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | – | RNA-sequencing transcriptome kits for health data analysis are developed. | |
| biofidelity.com | 2002 | Cambridge, United Kingdom | $59.91M | 28 | Molecular diagnostic assays are developed for target DNA sequence detection. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. | |
| seqwell.com | 2014 | Beverly, United States | $24.51M | 30 | NGS-based reagents and kits are supplied for life sciences research. | |
| sebia.com | 1967 | Evry Courcouronnes, France | – | – | Electrophoresis-based in vitro diagnostics products are developed and provided. | |
| nuprobe.com | 2016 | George Town, Cayman Islands | $61M | – | Sensitive multiplex platforms for QPCR are developed using toehold probes. |
Detailed competitors of Genomtec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomtec
Complete news archive for Genomtec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Genomtec
10 companies that operate in the same segment as Genomtec (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genomtec
Genomtec was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Genomtec is headquartered in Wrocław, Poland. It is registered at Wrocław, Lower Silesian Voivodeship, Poland.
Damian Andrzejewski is the current CEO of Genomtec.
Genomtec is a funded company, having raised a total of $4.38M across 6 funding rounds to date. The company's 1st funding round was a Grant of $2.29M, raised on Jan 2019.
Annual revenue of Genomtec is $5.85K as on Dec 31, 2025.
Genomtec was founded in 2016 in Wroclaw, Poland, and operates in the molecular diagnostics sector. A handheld point-of-care device is offered for isothermal amplification and detection of DNA and RNA fragments. Sample preparation is not required, and up to 10 samples or probes can be multiplexed in a single run. The focus remains on nucleic acid testing applications.
Genomtec's top competitors include Qiagen, Parse Biosciences and NuProbe.
Genomtec offers Genomtec ID, Genomtec Tumor, Genomtec SARS-CoV-2 EvaGreen, and Genomtec RT-LAMP Duo Kit.
Yes, Genomtec is publicly traded on GPW under the ticker symbol GMT.
Genomtec has 5 investors. Key investors include European Union, PARP, National Research Development Corporation, KnowledgeHub, and EIC Fund.
Genomtec operates through Genomtec S.A..